Photodynamic monotherapy or combination treatment with intravitreal triamcinolone acetonide, bevacizumab or ranibizumab for choroidal neovascularization associated with pathological myopia

Indian Journal of Ophthalmology

Volumn 59, Issue 3, 2011, Pages 242-246

  Rishi, Pukhraj ^a   Rishi, Ekta ^a   Venkataraman, Anusha ^a   Gopal, Lingam ^a   Sharma, Tarun ^a   Bhende, Muna ^a   Ratra, Dhanashree ^a   Sen, Pratik ^a   Sen, Parveen ^a  

^a SANKARA NETHRALAYA   (India)

Author keywords

Bevacizumab; choroidal neovascularization; intravitreal injection; myopia; photodynamic therapy; ranibizumab; triamcinolone acetonide; vascular endothelial growth factor

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; MONOCLONAL ANTIBODY; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE;

ARTICLE; DEGENERATIVE MYOPIA; DRUG COMBINATION; HUMAN; INTRAVITREAL DRUG ADMINISTRATION; PHOTOCHEMOTHERAPY; RETROSPECTIVE STUDY; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; HUMANS; INTRAVITREAL INJECTIONS; MYOPIA, DEGENERATIVE; PHOTOCHEMOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE;

EID: 79957536797     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.81049     Document Type: Article

References (11)

1. Yoshida T, Ohno-Matsui K, Yasuzumi K, Kojima A, Shimada N, Futagami S, et al. Myopic choroidal neovascularization: A 10-year follow-up. Ophthalmology 2003;110:1297-305. (Pubitemid 36842462)
2. Blinder KJ, Blumenkranz MS, Bressler NM, Bressler SB, Donato G, Lewis H, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003;110:667-73.
3. Yamamoto I, Rogers AH, Reichel E, Yates PA, Duker JS. Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularistaion secondary to pathological myopia. Br J Ophthalmol 2007;91:157-60. (Pubitemid 46202862)
4. Silva RM, Ruiz-Moreno JM, Nascimento J, Carneiro A, Rosa P, Barbosaa A, et al. Short-term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008;28:1117-23.
5. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularizationsecondary to pathological myopia: A pilot study. Br J Ophthalmol 2007;91:174-9. (Pubitemid 46202864)
6. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials--TAP report: Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-45.
7. Krebs I, Binder S, Stolba U, Glittenberg C, Brannath W, Goll A. Choroidal neovascularizationin Pathologic Myopia: Three-year results after PDT. Am J Ophthalmol 2005;140:416-25.
8. Montero JA, Ruiz-Moreno JM. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularizationsecondary to pathological myopia: A pilot study. Br J Ophthalmol 2007;91:131-3. (Pubitemid 46202852)
9. Rheaume MA, Sebag M. Intravitreal Bevacizumab for the treatment of CNV associated with pathological myopia. Can J Ophthalmol 2008;43:576-80.
10. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M, et al. Intravitreal injection of bevacizumab (Avastin) for subfoveal choroidal neovascularistaion associated with pathological myopia. Br J Ophthalmol 2007;91:161-5. (Pubitemid 46202863)
11. Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006;47:371-6. (Pubitemid 46780838)